IgM B. burgdorferi Antigen (AG) Test: Early Antibody Marker for Lyme Disease
Overview
The IgM B. burgdorferi Antigen (AG) test detects early-stage antibodies against Borrelia burgdorferi, the spirochete bacterium responsible for Lyme disease. Unlike subspecies- or protein-specific assays, this test measures IgM antibodies directed against a broader set of Borrelia antigens, improving sensitivity and making it a valuable tool in the early detection of Lyme borreliosis.
The Role of IgM Antibodies
IgM is the first class of antibodies produced by the immune system during infection. In Lyme disease:
-
IgM typically appears 1–2 weeks after a tick bite
-
Peaks during the first month of infection
-
Declines as IgG antibodies become more dominant
Measuring IgM against Borrelia antigens provides insight into a recent or active immune response, making it particularly useful in identifying early-stage infection.
Clinical Significance
A positive IgM response against B. burgdorferi antigens suggests a possible recent infection. This is especially relevant for patients with:
-
Early Lyme symptoms such as erythema migrans (bull’s-eye rash), fever, fatigue, headache, or muscle aches
-
Neurological manifestations including cranial neuritis, meningitis, or cognitive changes
-
Musculoskeletal involvement such as migratory joint pain or early Lyme arthritis
Because IgM reflects the early immune response, this marker can support recognition of Lyme disease before complications such as arthritis, carditis, or neuroborreliosis develop.
Limitations and Considerations
-
False positives may occur due to cross-reactivity with other infections or autoimmune conditions
-
Isolated IgM positivity without subsequent IgG development, particularly beyond 6–8 weeks of symptoms, may not indicate active infection
-
Persistent IgM antibodies can be detected in some individuals even after treatment, making clinical context essential
-
Additional testing with subspecies markers (B. afzelii, B. garinii) or antibodies to Outer Surface Proteins (OspA, OspC, OspE) can improve diagnostic accuracy when interpreted alongside IgM AG results
Broader Context in Lyme Testing
Traditional Lyme serology, such as ELISA and Western Blot, measures antibodies to mixtures of Borrelia proteins. While sensitive, these methods may lack specificity. Newer multi-antigen ELISA and next-generation immunoserology approaches combine cultured Borrelia antigens with in vivo–expressed proteins, allowing for more precise differentiation between Lyme disease and other conditions. The IgM B. burgdorferi AG test remains a foundational early marker within this broader testing strategy.
Summary
The IgM B. burgdorferi Antigen (AG) test captures the body’s early antibody response to Lyme disease. A positive result may support the diagnosis of a recent or ongoing infection, but it should never be interpreted in isolation. Results are most informative when combined with clinical history, symptom timing, IgG antibodies, and confirmatory testing. As part of a comprehensive serologic panel, this marker plays a key role in the early identification and management of Lyme disease, helping to prevent progression to later-stage complications.
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.